HLA antigens in Greek patients with thyrotoxicosis (Graves’ disease and toxic nodular goiter)

1984 ◽  
Vol 7 (4) ◽  
pp. 283-286 ◽  
Author(s):  
C. Papasteriades ◽  
Maria N. Alevizaki-Harhalaki ◽  
J. Economidou ◽  
D. G. Ikkos
Keyword(s):  
Hla Antigens ◽  
Nodular Goiter ◽  
Graves Disease ◽  
Toxic Nodular Goiter

scholarly journals Radioiodine Treatment of Hyperthyroidism—Prognostic Factors for Outcome

2001 ◽  
Vol 86 (8) ◽  
pp. 3611-3617 ◽  
Author(s):  
Amit Allahabadia ◽  
Jacquie Daykin ◽  
Michael C. Sheppard ◽  
Stephen C. L. Gough ◽  
Jayne A. Franklyn
Keyword(s):  
Single Dose ◽  
Prognostic Factors ◽  
Nodular Goiter ◽  
Fixed Dose ◽  
Graves Disease ◽  
Cure Rate ◽  
Toxic Nodular Goiter ◽  
Large Size ◽  
Lower Cure Rate ◽  
Lower Cure

There is little consensus regarding the most appropriate dose regimen for radioiodine (131I) in the treatment of hyperthyroidism. We audited 813 consecutive hyperthyroid patients treated with radioiodine to compare the efficacy of 2 fixed-dose regimens used within our center (185 megabequerels, 370 megabequerels) and to explore factors that may predict outcome. Patients were categorized into 3 diagnostic groups: Graves’ disease, toxic nodular goiter, and hyperthyroidism of indeterminate etiology. Cure after a single dose of 131I was investigated and defined as euthyroid off all treatment for 6 months or T4 replacement for biochemical hypothyroidism in all groups. As expected, patients given a single dose of 370 megabequerels had a higher cure rate than those given 185 megabequerels, (84.6% vs. 66.6%, P < 0.0001) but an increase in hypothyroidism incidence at 1 yr (60.8% vs. 41.3%, P < 0.0001). There was no difference in cure rate between the groups with Graves’ disease and those with toxic nodular goiter (69.5% vs. 71.4%; P, not significant), but Graves’ patients had a higher incidence of hypothyroidism (54.5% vs. 31.7%, P< 0.0001). Males had a lower cure rate than females (67.6% vs. 76.7%, P = 0.02), whereas younger patients (<40 yr) had a lower cure rate than patients over 40 yr old (68.9% vs. 79.3%, P < 0.001). Patients with more severe hyperthyroidism (P < 0.0001) and with goiters of medium or large size (P < 0.0001) were less likely to be cured after a single dose of 131I. The use of antithyroid drugs, during a period 2 wk before or after 131I, resulted in a significant reduction in cure rate in patients given 185 megabequerels 131I (P < 0.01) but not 370 megabequerels. Logistic regression analysis showed dose, gender, goiters of medium or large size, and severity of hyperthyroidism to be significant independent prognostic factors for cure after a single dose of 131I. We have demonstrated that a single fixed dose of 370 megabequerels 131I is highly effective in curing toxic nodular hyperthyroidism as well as Graves’ hyperthyroidism. Because male patients and those with more severe hyperthyroidism and medium or large-sized goiters are less likely to respond to a single dose of radioiodine, we suggest that the value of higher fixed initial doses of radioiodine should be evaluated in these patient categories with lower cure rates.

SEQUENTIAL OCCURRENCE OF TOXIC NODULAR GOITER FOLLOWED BY GRAVES' DISEASE

1998 ◽  
Vol 4 (3) ◽  
pp. 150-152 ◽  
Author(s):  
Alan H. Seplowitz, MD ◽  
Beth Ann Ditkoff, MD ◽  
Anastasios D. Papadopoulos, MD ◽  
Paul Lo Gerfo, MD
Keyword(s):  
Nodular Goiter ◽  
Graves Disease ◽  
Toxic Nodular Goiter

Graves' Disease and Toxic Nodular Goiter Are Both Associated with Increased Mortality But Differ with Respect to the Cause of Death: A Danish Population-Based Register Study

Thyroid ◽  
2013 ◽  
Vol 23 (4) ◽  
pp. 408-413 ◽  
Author(s):  
Frans Brandt ◽  
Marianne Thvilum ◽  
Dorthe Almind ◽  
Kaare Christensen ◽  
Anders Green ◽  
...  
Keyword(s):  
Cause Of Death ◽  
Nodular Goiter ◽  
Population Based ◽  
Register Study ◽  
Graves Disease ◽  
Danish Population ◽  
Toxic Nodular Goiter

scholarly journals Serum thyroglobulin level in newly detected thyrotoxicosis and its role in differential diagnosis of thyrotoxicosis

2021 ◽  
Vol 8 (3) ◽  
pp. 433
Author(s):  
Mohammad Omar Faruque ◽  
A. B. M. Kamrul-Hasan ◽  
M. Ahamedul Kabir ◽  
Rehnuma Nasim ◽  
Mohammad Jahangir Alam ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Elevated Serum ◽  
Nodular Goiter ◽  
Tertiary Hospital ◽  
Subacute Thyroiditis ◽  
Graves Disease ◽  
Serum Thyroglobulin ◽  
Cross Sectional ◽  
Toxic Nodular Goiter ◽  
Thyroglobulin Level

Background: Elevated serum thyroglobulin (Tg) level is commonly observed in various forms of thyrotoxicosis; the levels vary according to different etiologies. This study aimed at identifying the value of serum Tg level in the differential diagnosis of common etiologies of thyrotoxicosis.  Methods: This cross-sectional study was conducted at the endocrine outpatient department of a tertiary hospital in Bangladesh from March 2015 to May 2017. In this study, 200 subjects with newly detected untreated thyrotoxicosis were evaluated. Serum Tg was assayed by chemiluminescent immunometric assay.  Results: Serum Tg level was raised in 48% of subjects. Subjects aged ≥40 years, and those having a family history of thyroid disorders had relatively higher thyroglobulin levels. The frequency of subjects with an elevated Tg was highest in subacute thyroiditis (89.5%) followed by toxic nodular goiter (77.3%) and Graves’ disease (32.9%); the difference in the frequencies was statistically significant (p<0.001). Median Tg was highest in the subjects with subacute thyroiditis (132.6 ng/ml) followed by toxic nodular goiter (99.55 ng/ml); those with Graves’ disease had the lowest Tg level (12.5 ng/ml); the differences in median Tg levels across the three groups were also statistically significant (p<0.001).  Conclusions: Serum thyroglobulin level may be useful for the etiological diagnosis of thyrotoxicosis.

Determinants of Visfatin/NAMPT Serum Concentration and its Leukocyte Expression in Hyperthyroidism

2018 ◽  
Vol 50 (09) ◽  
pp. 653-660 ◽  
Author(s):  
Nadia Sawicka-Gutaj ◽  
Ariadna Zybek-Kocik ◽  
Michał Kloska ◽  
Agata Czarnywojtek ◽  
Jerzy Sowiński ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Serum Concentration ◽  
Thyroid Autoimmunity ◽  
Nodular Goiter ◽  
Stepwise Multiple Regression ◽  
Graves Disease ◽  
Stepwise Multiple Regression Analysis ◽  
Mass Percentage ◽  
Toxic Nodular Goiter ◽  
Hyperthyroid Patients

AbstractWe aimed to analyze the potential influence of thyroid autoimmunity on visfatin/NAMPT serum concentration and its leukocyte expression in hyperthyroid patients. This is a single-center, cross-sectional study with consecutive enrollment. All patients with newly diagnosed overt hyperthyroidism in a course of Graves' disease or toxic nodular goiter were included in the study. They underwent physical examination, laboratory investigation, body composition analysis, and thyroid ultrasound. NAMPT mRNA leukocyte expressions were measured using RT-qPCR. Of the 173 patients, 95 were enrolled in further analysis [67 patients with Graves' disease (GD) and 28 with toxic nodular goiter (TNG)]. Control group consisted of 43 healthy volunteers adjusted for age, sex, and BMI. Higher NAMPT/visfatin serum concentration was found in patients with GD comparing with patients with TNG (p=0.03855). We found significant NAMPT leukocyte overexpression in GD patients (n=32) as compared to TNG patients (n=18) and euthyroid controls (n=24) (p=0.005965). Simple linear regression analysis revealed that NAMPT/visfatin serum concentration was significantly associated with NAMPT leukocyte expression, thyroid autoimmunity, age, HOMA-IR, and fat mass percentage (FM%). NAMPT leukocyte expression was related to thyroid autoimmunity, age, and TRAb levels. The stepwise multiple regression analysis revealed FM% and HOMA-IR as independent predictors of visfatin/NAMPT serum levels. In a separate stepwise multiple regression analysis, we confirmed the association between NAMPT leukocyte expression and TRAb levels. We found that fat mass percentage together with HOMA-IR are the most significant predictors of visfatin/NAMPT serum elevation in hyperthyroid patients.

Sign in / Sign up

Export Citation Format

Share Document